BEIJING, June 26, 2025 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, today announced financial results for the six months ended March 31, 2025.Business Accomplishments and Highlights for the Six Months Ended March 31, 2025, and to date:Strategic Partnerships and Commercialization: In October 2024, Origin established the "Origin Marker Biological Breeding Service Consortium" in partnership with China Golden Marker Biotechno ...

Company Overview - Lifeway Foods, Inc. is a leading U.S. supplier of kefir and fermented probiotic products, recognized as one of Forbes' Best Small Companies [3] - The company produces a variety of products including drinkable kefir, cheeses, and a ProBugs line for kids, with distribution across the U.S., Mexico, Ireland, South Africa, UAE, and France [3] Product Highlights - Lifeway's Berry Blast Probiotic Smoothie + Collagen has won Good Housekeeping's 2025 Snack Awards, highlighting its market recognition [1] - The smoothie contains 5 grams of hydrolyzed collagen per bottle, supporting skin health and joint support, along with 12 live and active probiotic cultures and billions of beneficial CFUs [1][2] - The product is lactose-free and gluten-free, catering to rising consumer demand for functional dairy products [2] Market Trends - The introduction of the Probiotic Smoothie + Collagen line, which includes flavors like Matcha Latte and Tropical Fruit, responds to increasing consumer interest in gut-skin health connections [2]

Khaveen Investments is a global Investment Advisory Firm dedicated to serving the investment needs of clients worldwide including high-net-worth individuals, corporations, associations, and institutions. We provide comprehensive services ranging from market and security research to business valuation and wealth management. Our flagship Macroquantamental Hedge Fund maintains a diversified portfolio with exposure to hundreds of investments across various asset classes, geographies, sectors, and industries. We ...

证 券 研 究 报 告 炬芯科技（688049）深度研究报告 强推（首次） 首发 CIM 产品卡位端侧 AI 黄金赛道，新品 放量业绩持续高增 ❖ 风险提示：蓝牙音箱出货不及预期、客户导入不及预期、技术发展不及预期 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 652 | 910 | 1,193 | 1,541 | | 同比增速(%) | 25.3% | 39.6% | 31.1% | 29.1% | | 归母净利润(百万) | 107 | 173 | 235 | 317 | | 同比增速(%) | 63.8% | 62.1% | 36.2% | 34.6% | | 每股盈利(元) | 0.73 | 1.18 | 1.61 | 2.17 | | 市盈率(倍) | 79 | 49 | 36 | 27 | | 市净率(倍) | 4.5 | 4.2 | 3.8 | 3.4 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 6 月 25 日收盘价 公司研究 集成电路 2025 年 06 ...

Collaborating on Establishing "Blockchain + Stablecoin + Smart Cold Chain" Smart Agricultural EcosystemHONG KONG, June 26, 2025 (GLOBE NEWSWIRE) -- Reitar Logtech Holdings Limited (NASDAQ: RITR) (“Reitar” or the “Company”), a pioneer in providing comprehensive "Property Logistics Technology (PLT)" solutions, today announced the signing of a strategic Memorandum of Understanding (the “MOU”) with Rich Harvest Agricultural Produce Limited (“Rich Harvest”), a leading Asian smart agriculture enterprise. With eig ...

American Rebel Holdings Inc American Rebel Light Beer Online Orders Soar as American Rebel Beer Ships to Over 40 States; Free Shipping Available Through June 30 NASHVILLE, TN, June 26, 2025 (GLOBE NEWSWIRE) -- American Rebel Holdings, Inc. (NASDAQ: AREB) ("American Rebel" or the "Company"), creator of American Rebel Beer (americanrebelbeer.com) and a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel, proudly reports explosive online sales grow ...

Core Insights - Plus Therapeutics is set to launch its CNSide CSF Assay Platform in the U.S. market in the second half of 2025, targeting a significant unmet need in CNS cancer diagnostics with a market opportunity exceeding $6 billion [1][2][4] Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for central nervous system (CNS) cancers [14] - The company has invested over $300 million in the CNSide technology, which aims to address the clinical need for better diagnostic tools in CNS cancer [3] Product Details - The CNSide CSF Assay Platform is designed for patients suspected of having CNS cancer metastases, with the first test, CNSide CSF Tumor Cell Enumeration (TCE), expected to be commercialized soon [2][4] - The platform has demonstrated high sensitivity (92%) and specificity (95%) in diagnosing CNS metastases, influencing treatment decisions in 90% of cases [5] Market Opportunity - CNS metastases affect approximately 30% of adult cancer patients, and the current standard of care for diagnosis is outdated, leading to missed or delayed diagnoses [4] - The CNSide platform is positioned to provide superior clinical utility compared to the current standard of care, which has been validated through real-world use and peer-reviewed publications [5] Commercial Strategy - Plus Therapeutics has established a scalable testing laboratory in Houston, TX, and is executing a commercial market access strategy that includes state licensure and reimbursement codes [6][7] - The company anticipates launching the CNSide platform in Texas first, followed by expansion into additional states [6] Financial Outlook - The revenue contributions from the CNSide subsidiary are expected to become meaningful to Plus Therapeutics' operations in fiscal year 2026 [9]

Lantronix Edge Intelligent Gateways and Percepxion Platform to Improve Network Resilience, Reduce Service Disruptions and Cut Operational CostsIRVINE, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX), a global leader of compute and connectivity IoT solutions enabling Edge AI Intelligence, today announced a multi-year agreement with a Tier-1 U.S. mobile network operator to digitally transform the management of more than 50,000 backup power systems across wireless cell sites nationwide. ...

瑞财经 吴文婷6月25日，上海商米科技集团股份有限公司（以下简称"商米科技"）在港交所递交招股 书，德意志银行、中信证券和农银国际为联席保荐人。 根据灼识谘询的资料，按2024年的收入计，公司目前是全球最大的安卓端BIoT解决方案提供商，占有 10%以上的市场份额。根据同一资料来源，预期安卓端BIoT解决方案市场将于未来五年出现爆发式增 长。 商米科技是商业物联网(BIoT)解决方案提供商。公司的颠覆性解决方案集成了智能硬件、软件及数据洞 察，赋能众多线下商业场景实现数字化转型，提升核心商业运营流程(如支付、会员管理、订单履约、 存货控制及员工管理)效率。 据招股书，2022年-2024年，商米科技实现收入分别为34.04亿元、30.71亿元、34.56亿元；年内利润分 别为1.6亿元、1.01亿元、1.81亿元。 | | | 截至12月31日止年度 | | | --- | --- | --- | --- | | | 2022年 | 2023年 | 2024年 | | | | (人民幣千元) | | | 收入 | 3,404,380 | 3,070,569 | 3,456,377 | | 銷售成本 | (2, ...

香港资本市场正迎来科技企业上市的新热潮，AIoT企业特斯联成为此轮赴港IPO浪潮中的焦点。数据显示，2025年1月至4月，已有19家企业成功登陆 港股，较去年同期增加4家，募集资金总额达213亿港元，接近去年同期的三倍。截至5月20日，共有24家公司在香港主板上市，合计募集资金突破 600亿港元。目前排队等待上市的企业数量已攀升至约150家，其中，特斯联是2025年预在港上市的最大AI企业。 值得一提的是，特斯联强劲的业务表现，也持续吸引着更多资本的加持。2025年初，特斯联成功完成D++轮融资，引入青岛汇铸、青岛得厚等国有资 本及诺哲瑞英、上海瑞力等产业基金，为IPO征程奠定了坚实的资金基础。 目前，特斯联围绕"空间智能"核心，确立了AIoT领域模型、AIoT基础设施及AIoT智能体三大战略方向。其技术体系已在实际落地项目中获得充分验 证，展现出将前沿AI能力转化为产业价值的实力。截至2024年末，特斯联在手订单金额已达23亿元，其AI产业数智化业务收入同比飙升162.9%，达 16.4亿元，占总收入比重高达89%。 在此次港股上市热潮之中，特斯联凭借行业领先的增速、聚焦的业务战略及已验证的技术路径，不仅成 ...